Enzyme-Catalyzed Activation of Anticancer Prodrugs
暂无分享,去创建一个
Nico P E Vermeulen | Martijn Rooseboom | N. Vermeulen | J. Commandeur | M. Rooseboom | Jan N M Commandeur
[1] R. Begent,et al. First clinical experience with ADEPT , 1996 .
[2] Y. Moriwaki,et al. Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. , 2001, Histology and histopathology.
[3] W. Sadee,et al. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil. , 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[4] H. Svensson,et al. In Vitro and In Vivo Activities of a Doxorubicin Prodrug in Combination with Monoclonal Antibody β-Lactamase Conjugates , 1995 .
[5] K. Nakanishi,et al. Studies on menadione reductase of bakers' yeast. II. Inhibition of the enzyme activity by NAD and stimulation of that by p-chloromercuribenzoate. , 1965, Journal of biochemistry.
[6] Y. Nio,et al. Antitumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs. , 1992, Anticancer research.
[7] S. Ozawa,et al. Expression of CYP2A6 in Tumor Cells Augments Cellular Sensitivity to Tegafur , 2001, Japanese journal of cancer research : Gann.
[8] R. Blaese,et al. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] W. Bloomer,et al. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells. , 1993, Biochemical pharmacology.
[10] G. A. Hamilton. Peroxisomal oxidases and suggestions for the mechanism of action of insulin and other hormones. , 2006, Advances in enzymology and related areas of molecular biology.
[11] A. Sartorelli,et al. Potential Bioreductive Alkylating Agents , 1976 .
[12] Curtis D. Klaassen,et al. Casarett and Doull's Toxicology. The Basic Science of Poisons , 1981 .
[13] Y. Hara,et al. Partial purification of a thymidine phosphorylase from human gastric cancer. , 1986, Chemical & pharmaceutical bulletin.
[14] H. Haisma,et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer , 2001, British Journal of Cancer.
[15] X. Breakefield,et al. Prodrug activation enzymes in cancer gene therapy , 2000, The journal of gene medicine.
[16] A. Epenetos,et al. Targeting enzymes for cancer therapy: old enzymes in new roles. , 1994, British Journal of Cancer.
[17] J. Eble,et al. Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation. , 1988, Cancer biochemistry biophysics.
[18] T. Doyle,et al. Synthesis and biological evaluation of a water soluble phosphate prodrug of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP). , 1998, Bioorganic & medicinal chemistry letters.
[19] J. Laszlo,et al. Biochemical effects of the methyl ester of streptonigrin. , 1966, Biochemical pharmacology.
[20] T. Suzuki,et al. Catalytic action of L-methionine gamma-lyase on selenomethionine and selenols. , 1979, Biochemistry.
[21] D. Waxman,et al. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. , 2000, Biochemical pharmacology.
[22] R. Champlin. Peripheral blood progenitor cells: a replacement for marrow transplantation? , 1996, Seminars in oncology.
[23] F. Friedlos,et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). , 1992, Biochemical pharmacology.
[24] A. Bolzán,et al. Genotoxicity of streptonigrin: a review. , 2001, Mutation research.
[25] M. Tomasz,et al. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. , 1998, Biochemical pharmacology.
[26] C. Fairchild,et al. Synthesis and antitumor evaluation of 2′-oxycarbonylpaclitaxels (paclitaxel-2′-carbonates) , 1994 .
[27] H. Yamazaki,et al. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] N. Rainov,et al. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma , 2000, Cancer Gene Therapy.
[29] C. Ip,et al. Lessons from basic research in selenium and cancer prevention. , 1998, The Journal of nutrition.
[30] M. Tomasz,et al. Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C. , 1997, Biochemistry.
[31] S. Rockwell,et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. , 1993, International journal of radiation oncology, biology, physics.
[32] M. Kavarana,et al. A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides. , 1999, Journal of medicinal chemistry.
[33] S. Ito,et al. 4-S-cysteaminylphenol and its analogues as substrates for tyrosinase and monoamine oxidase. , 1990, Pigment cell research.
[34] W. Shearer,et al. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. , 1973, Journal of immunology.
[35] S. Rockwell,et al. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. , 1998, Advances in enzyme regulation.
[36] T. Yamashita,et al. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. , 1999, The Journal of investigative dermatology.
[37] H. Shepard,et al. A novel approach to thymidylate synthase as a target for cancer chemotherapy. , 2001, Molecular pharmacology.
[38] T. Furukawa,et al. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. , 1990, Biochimica et biophysica acta.
[39] A. Harris,et al. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines? , 1999, British Journal of Cancer.
[40] J. Seidenberg,et al. DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES. , 1964, The Journal of biological chemistry.
[41] K. Wakamatsu,et al. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol. , 1997, Biochemical pharmacology.
[42] C. Monneret,et al. Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy , 1999 .
[43] P. Remondelli,et al. In vitro activation of isophosphamide and trophosphamide to metabolites mutagenic for bacteria. , 1986, Toxicology letters.
[44] E. Wintersberger. Regulation and biological function of thymidine kinase. , 1997, Biochemical Society transactions.
[45] K. Bush,et al. Synthesis and release of doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate , 1993 .
[46] C. Walsh,et al. Studies on the mechanism of action of D-amino acid oxidase. Evidence for removal of substrate -hydrogen as a proton. , 1971, The Journal of biological chemistry.
[47] V. Santini. Amifostine: chemotherapeutic and radiotherapeutic protective effects , 2001, Expert opinion on pharmacotherapy.
[48] F. Friedlos,et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. , 1992, Biochemical pharmacology.
[49] J. Kralovánszky,et al. Putative Role of Dihydropyrimidine Dehydrogenase in the Toxic Side Effect of 5-Fluorouracil in Colorectal Cancer Patients , 1998, Oncology.
[50] B. Hammock,et al. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. , 1996, Cancer research.
[51] R. Lindahl,et al. Activity of various aldehyde-metabolizing enzymes in chemically-induced rat hepatomas. , 1982, Biochemical pharmacology.
[52] H. Ishitsuka,et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. , 2000, Bioorganic & medicinal chemistry.
[53] P. Senter,et al. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. , 1993, Journal of medicinal chemistry.
[54] J. Backman,et al. The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans , 1997 .
[55] N. Siemers,et al. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. , 1999, Bioconjugate chemistry.
[56] T. Sakai,et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. , 1985, Cancer research.
[57] H. Ganther,et al. Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. , 1999, Anticancer research.
[58] J. Reid,et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] J. Wands,et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the escherichia coli purine nucleoside phosphorylase gene , 2000, Hepatology.
[60] G. Schreiber,et al. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. , 1995, Cancer research.
[61] K. Soda. Microbial sulfur amino acids: an overview. , 1987, Methods in enzymology.
[62] N. Vermeulen,et al. Bioactivation of chemopreventive selenocysteine Se-conjugates and related amino acids by amino acid oxidases novel route of metabolism of selenoamino acids. , 2001, Chemical research in toxicology.
[63] D. Ross,et al. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. , 1990, Cancer research.
[64] K. Hande,et al. Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.
[65] D. Ross,et al. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. , 1994, Oncology research.
[66] B. Mitchell,et al. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. , 1996, Cancer research.
[67] G. R. Fisher,et al. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase. , 1991, Free radical biology & medicine.
[68] H. Haisma,et al. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. , 1999, Biochemical pharmacology.
[69] W. Aldridge. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. , 1953, The Biochemical journal.
[70] L. Kaiser,et al. Cancer chemotherapy using suicide genes. , 1998, Surgical oncology clinics of North America.
[71] Y. Choong,et al. Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues. , 1988, Experimental pathology.
[72] P. Workman,et al. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. , 1992, International journal of radiation oncology, biology, physics.
[73] L. D. Stegman,et al. Induction of cytotoxic oxidative stress by D-alanine in brain tumor cells expressing Rhodotorula gracilis D-amino acid oxidase: a cancer gene therapy strategy. , 1998, Human gene therapy.
[74] E. Gallagher,et al. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. , 1995, Toxicology and applied pharmacology.
[75] A. López de Cerain,et al. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. , 1999, European journal of cancer.
[76] B. Hultberg,et al. Tissue content and localization of lysosomal enzymes in cholestatic rats. , 1986, Scandinavian journal of gastroenterology.
[77] R. Byrd,et al. A purified cysteine conjugate beta-lyase from rat kidney cytosol. Requirement for an alpha-keto acid or an amino acid oxidase for activity and identity with soluble glutamine transaminase K. , 1986, The Journal of biological chemistry.
[78] P. Cuq,et al. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase , 1999, British Journal of Cancer.
[79] W. Fishman. The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. , 1995, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[80] D. Waxman,et al. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. , 1999, Drug metabolism reviews.
[81] S. J. Johnston,et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer , 2001, International journal of cancer.
[82] A. Jaiswal,et al. Non‐enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity , 1996, International journal of cancer.
[83] J. Yuhas. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. , 1980, Cancer research.
[84] R. Hughey,et al. Gamma-glutamyltranspeptidase expression regulates the growth-inhibitory activity of the anti-tumor prodrug gamma-L-glutaminyl-4-hydroxy-3-iodobenzene. , 1994, International journal of cancer.
[85] C. Monneret,et al. Direct in vivo observation of 5‐fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study , 2000, NMR in biomedicine.
[86] W. Plunkett,et al. Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production. , 1987, Biochemical pharmacology.
[87] K. Syrigos,et al. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. , 1999, Anticancer research.
[88] A. Harris,et al. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line , 2000, British Journal of Cancer.
[89] T. Doyle,et al. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. , 2001, Current medicinal chemistry.
[90] H. Villar,et al. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. , 1996, Journal of medicinal chemistry.
[91] G. Cohen,et al. In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[92] D. Santi,et al. The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.
[93] N. Vermeulen,et al. Synthesis of novel Se-substituted selenocysteine derivatives as potential kidney selective prodrugs of biologically active selenol compounds: evaluation of kinetics of beta-elimination reactions in rat renal cytosol. , 1996, Journal of medicinal chemistry.
[94] H. Pinedo,et al. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. , 1996, Biochemical pharmacology.
[95] E. Mimnaugh,et al. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. , 1975, Drug metabolism and disposition: the biological fate of chemicals.
[96] A. Sartorelli,et al. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. , 1972, Journal of medicinal chemistry.
[97] H. Haisma,et al. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. , 1992, British Journal of Cancer.
[98] J. Gilloteaux,et al. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. , 2001, The Journal of nutrition.
[99] V. del Marmol,et al. Tyrosinase and related proteins in mammalian pigmentation , 1996, FEBS letters.
[100] T. Skovsgaard,et al. Cellular resistance to anthracyclines. , 1996, General pharmacology.
[101] P. Workman,et al. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. , 1991, Cancer communications.
[102] C. Kwon. Metabolism-based anticancer drug design , 1999, Archives of pharmacal research.
[103] A. Harris,et al. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). , 1995, British Journal of Cancer.
[104] M. Tomasz,et al. Mitomycin C: small, fast and deadly (but very selective). , 1995, Chemistry & biology.
[105] Z. Bebők,et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. , 1994, Gene therapy.
[106] B. Ardalan,et al. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. , 1999, The cancer journal from Scientific American.
[107] N. Vermeulen,et al. Selenoxidation by flavin-containing monooxygenases as a novel pathway for beta-elimination of selenocysteine Se-conjugates. , 2001, Chemical research in toxicology.
[108] G. Schreiber,et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. , 1989, Cancer research.
[109] S. Briggs,et al. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. , 1993, Cancer research.
[110] S. Ito,et al. The in vivo antimelanoma effect of 4‐S‐cysteaminylphenol and its N‐acetyl derivative , 1990, International journal of cancer.
[111] K. Bosslet,et al. Tumor-selective prodrug activation by fusion protein-mediated catalysis. , 1994, Cancer research.
[112] W. Fishman. Isozymes, Tumor Markers and Oncodevelopmental Biology , 1995 .
[113] Y. Cheng,et al. 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. , 1995, Biochemical pharmacology.
[114] N. Vermeulen,et al. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. , 1995, Pharmacological reviews.
[115] Y. Maehara,et al. Species differences in substrate specificity of pyrimidine nucleoside phosphorylase , 1989, Journal of surgical oncology.
[116] G. Powis,et al. Cytosolic NAD(P)H:(Quinone‐acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol , 1990, International journal of cancer.
[117] F. Mȕller. Chemistry and Biochemistry of Flavoenzymes: Volume I , 1991 .
[118] T. E. Gram. Chemically reactive intermediates and pulmonary xenobiotic toxicity. , 1997, Pharmacological reviews.
[119] S. Keyes,et al. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. , 1984, Cancer research.
[120] P. Workman,et al. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? , 1989, British Journal of Cancer.
[121] H. Ishitsuka,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.
[122] C. Beedham,et al. Tissue distribution of the molybdenum hydroxylases, aldehyde oxidase and xanthine oxidase, in male and female guinea pigs. , 1987, European journal of drug metabolism and pharmacokinetics.
[123] H. Svensson,et al. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. , 1998, Journal of medicinal chemistry.
[124] J. Ward,et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. , 1985, International journal of radiation biology and related studies in physics, chemistry, and medicine.
[125] W. Jaeger,et al. Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.
[126] N. Vermeulen,et al. Tissue distribution of cytosolic beta-elimination reactions of selenocysteine Se-conjugates in rat and human. , 2002, Chemico-biological interactions.
[127] S. McKeown,et al. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. , 1998, International journal of radiation oncology, biology, physics.
[128] K. Kunugi,et al. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. , 1994, Cancer research.
[129] R. Donehower,et al. Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma , 2004, Investigational New Drugs.
[130] A. Harris,et al. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. , 1995, British Journal of Cancer.
[131] K. Tew,et al. Glutathione and related enzymes in multidrug resistance. , 1996, European journal of cancer.
[132] D. Hirst,et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N , 2001, British Journal of Cancer.
[133] K. Kunugi,et al. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[134] M. Iqbal,et al. Thymidylate synthase in normal and cancer tissues. , 1993, Biochemical Society transactions.
[135] P. van Bladeren. Glutathione conjugation as a bioactivation reaction. , 2000, Chemico-biological interactions.
[136] Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. , 1989, International journal of radiation oncology, biology, physics.
[137] L. Rivory. Metabolism of CPT‐11: Impact on Activity , 2000, Annals of the New York Academy of Sciences.
[138] H. Ishitsuka,et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine , 2004, Cancer Chemotherapy and Pharmacology.
[139] G. Dachs,et al. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives , 2001, Journal of cellular physiology.
[140] R. Spooner,et al. Genetic delivery of enzymes for cancer therapy. , 1995, Gene therapy.
[141] N. Vermeulen,et al. Bioactivation of selenocysteine Se-conjugates by a highly purified rat renal cysteine conjugate beta-lyase/glutamine transaminase K. , 2000, The Journal of pharmacology and experimental therapeutics.
[142] H. Niitani,et al. [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[143] W. Denny,et al. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia , 2000, Expert opinion on investigational drugs.
[144] A. Oliff,et al. Drug-targeting strategies in cancer therapy. , 2001, Current opinion in genetics & development.
[145] A. Patterson,et al. Enzymology of tirapazamine metabolism: a review. , 1998, Anti-cancer drug design.
[146] P. Low,et al. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. , 1999, Journal of drug targeting.
[147] T. Humphreys,et al. N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. , 1992, Cancer research.
[148] M. Wierdl,et al. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. , 2001, Molecular pharmacology.
[149] M. Tateishi,et al. Purification and characterization of human hepatic cysteine-conjugate beta-lyase. , 1986, The Biochemical journal.
[150] D. Kerr,et al. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide , 2005, Cancer Immunology, Immunotherapy.
[151] J. Stevens. Isolation and characterization of a rat liver enzyme with both cysteine conjugate beta-lyase and kynureninase activity. , 1985, The Journal of biological chemistry.
[152] T. Shepherd,et al. Synthesis of a cephalosporin-doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme , 1993 .
[153] K. Soda,et al. l-Methionine γ-lyase from Pseudomonas putida and Aeromonas , 1987 .
[154] O. Mcbride,et al. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. , 1990, Biochemistry.
[155] N. Bachur,et al. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[156] D. Hirst,et al. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine , 2000, British Journal of Cancer.
[157] M. D. de Broe,et al. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. , 1994, Critical reviews in clinical laboratory sciences.
[158] N. Vermeulen,et al. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. , 1999, Critical reviews in toxicology.
[159] S. Infusino,et al. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review). , 1999, Oncology reports.
[160] M. Gerken,et al. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard. , 2000, Bioorganic & medicinal chemistry letters.
[161] M. Christian,et al. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[162] A. Jaiswal. Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. , 1994, The Journal of biological chemistry.
[163] R. Morgenstern,et al. Comparison of the distribution of microsomal and cytosolic glutathione S-transferase activities in different organs of the rat. , 1983, Biochemical pharmacology.
[164] A. Boddy,et al. Metabolism and Pharmacokinetics of Oxazaphosphorines , 2000, Clinical pharmacokinetics.
[165] P. Carter,et al. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. , 1995, Chemistry & biology.
[166] D. Ross,et al. Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma. , 1990, Free radical research communications.
[167] B. Testa,et al. Concepts in drug metabolism , 1980 .
[168] G. Powis,et al. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. , 1995, Anticancer research.
[169] T. C. Jenkins,et al. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.
[170] Elazer R. Edelman,et al. Adv. Drug Delivery Rev. , 1997 .
[171] J. Laszlo,et al. Comparison of biochemical effects of isopropylidine azastreptonigrin (NSC-62709) with streptonigrin (NSC-45383). , 1967, Cancer chemotherapy reports.
[172] S. Demontis,et al. Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone. , 1999, The Biochemical journal.
[173] R. Jackson,et al. Increase in liver and kidney deoxycytidine kinase activity linked to neoplastic transformation. , 1980, Biochemical and biophysical research communications.
[174] H. Svensson,et al. Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates. , 1995, Journal of medicinal chemistry.
[175] H. Yamazaki,et al. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[176] J. Cummings,et al. Current issues in the enzymology of mitomycin C metabolic activation. , 1998, General pharmacology.
[177] Elias S. J. Arnér,et al. Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.
[178] D Shugar,et al. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. , 2000, Pharmacology & therapeutics.
[179] A. Dubreuil,et al. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis , 2001, British Journal of Cancer.
[180] H K Kroemer,et al. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[181] M. Poupon,et al. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard. , 1998, Anti-cancer drug design.
[182] Y. Miyake,et al. Studies on the reaction of D-amino acid oxidase with beta-cyano-D-alanine. Observation of an intermediary stable charge transfer complex. , 1980, Journal of biochemistry.
[183] J. Pawelek,et al. New regulators of melanin biosynthesis and the autodestruction of melanoma cells , 1980, Nature.
[184] R. Hughey,et al. γ‐glutamyltranspeptidase expression regulates the growth‐inhibitory activity of the anti‐tumor prodrug γ‐L‐glutaminyl‐4‐hydroxy‐3‐iodobenzene , 1994 .
[185] A. Schally,et al. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. , 1999, European journal of endocrinology.
[186] G. Schreiber,et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[187] J. Givel,et al. Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours. , 1994, European journal of cancer.
[188] H. Svensson,et al. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. , 1995, Cancer research.
[189] R. Weissleder,et al. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. , 2000, Cancer research.
[190] J. Brown,et al. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. , 1993, British Journal of Cancer.
[191] H. W. Scheeren,et al. Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. , 1999, Bioorganic & medicinal chemistry.
[192] H. Lehnert,et al. Clinical management of malignant adrenal tumors , 2001, Journal of Cancer Research and Clinical Oncology.
[193] M. Makuuchi,et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. , 2001, Cancer research.
[194] F. Baumann,et al. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide , 2002, Journal of Cancer Research and Clinical Oncology.
[195] M. Boyd,et al. Isolation and characterization of 4-ipomeanol, a lung-toxic furanoterpenoid produced by sweet potatoes (Ipomoea batatas). , 1972, Journal of agricultural and food chemistry.
[196] H. Svensson,et al. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. , 1993, Bioconjugate chemistry.
[197] I. Stupans,et al. Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues. , 1989, Carcinogenesis.
[198] J. Chern,et al. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). , 1999, Journal of medicinal chemistry.
[199] H. Ganther,et al. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. , 2000, Cancer research.
[200] R. Diasio,et al. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. , 1980, Cancer research.
[201] C. A. Ramsden,et al. Melanogenesis-targeted anti-melanoma prodrug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model system , 1995 .
[202] H. Svensson,et al. Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates. , 1997, Journal of medicinal chemistry.
[203] M. Boyd. Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung , 1977, Nature.
[204] M. Epperly,et al. Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cells. , 1992, Cancer letters.
[205] H. Kroemer,et al. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide , 1999, Cancer Chemotherapy and Pharmacology.
[206] A. Parkinson,et al. Alterations in expression of CYP1A1 and NADPH-cytochrome P450 reductase during lung tumor development in SWR/J mice. , 1996, Carcinogenesis.
[207] T. Kinsella. An approach to the radiosensitization of human tumors. , 1996, The cancer journal from Scientific American.
[208] R. Parks,et al. 16 Purine Nucleoside Phosphorylase , 1972 .
[209] P. Russell,et al. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[210] A. Herzfeld,et al. Relative activities of thymidylate synthetase and thymidine kinase in rat tissues. , 1980, Cancer research.
[211] F. Giles,et al. The potential of amifostine: from cytoprotectant to therapeutic agent. , 1999, Haematologica.
[212] K. Fukui,et al. D-amino-acid oxidase is not present in the mouse liver. , 1997, Biochimica et biophysica acta.
[213] F. Maerki,et al. [Vitamin K reductase, preparation and properties]. , 1960, Biochemische Zeitschrift.
[214] A. Harris,et al. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. , 1997, British Journal of Cancer.
[215] M. Lyttle,et al. Glutathione-S-transferase activates novel alkylating agents. , 1994, Journal of medicinal chemistry.
[216] C. Efthymiopoulos,et al. Effect of Food and Gastric pH on the Bioavailability of Grepafloxadn , 1997, Clinical pharmacokinetics.
[217] D. M. Goldberg,et al. Development of a fluorometric assay for amino-acid oxidase activity and its application to the study of human tissues. , 1982, Biochemical medicine.
[218] A. Elfarra,et al. Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats. , 1999, The Journal of pharmacology and experimental therapeutics.
[219] K. Soda,et al. L-methionine gamma-lyase from Pseudomonas putida and Aeromonas. , 1987, Methods in enzymology.
[220] A. Begleiter,et al. Clinical applications of quinone-containing alkylating agents. , 2000, Frontiers in bioscience : a journal and virtual library.
[221] S. Hanessian,et al. Design and synthesis of a cephalosporin–carboplatinum prodrug activatable by a β-lactamase , 1993 .
[222] M. Tateishi,et al. Cysteine conjugate beta-lyase in rat liver. A novel enzyme catalyzing formation of thiol-containing metabolites of drugs. , 1978, The Journal of biological chemistry.
[223] A. Y. Lu,et al. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. , 2001, Annual review of pharmacology and toxicology.
[224] P. Workman,et al. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. , 2001, Biochemical pharmacology.
[225] Elias S. J. Arnér,et al. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. , 1992, Biochemical and biophysical research communications.
[226] S. McKeown,et al. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. , 1999, Anti-cancer drug design.
[227] ADRIEN ALBERT,et al. Chemical Aspects of Selective Toxicity , 1958, Nature.
[228] R. Bicknell,et al. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. , 1998, The Biochemical journal.
[229] T. Slater,et al. NADPH-cytochrome c reductase, cytochrome P-450 and NADPH-linked lipid peroxidation in microsomal fractions obtained from rat tissue. , 1976, Biochemical Society transactions.
[230] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[231] M. Spiteri,et al. Glutathione-S-transferase family of enzymes. , 2001, Mutation research.
[232] L. Amzel,et al. Molecular Basis of the Catalytic Differences among DT-diaphorase of Human, Rat, and Mouse* , 1997, The Journal of Biological Chemistry.
[233] M. Rosenblum,et al. Intensely cytotoxic anthracycline prodrugs: glucuronides. , 1997, Journal of medicinal chemistry.
[234] Y. Moriwaki,et al. Distribution and pathophysiologic role of molybdenum-containing enzymes. , 1997, Histology and histopathology.
[235] P. Senter. Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[236] R. Stroud,et al. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. , 2001, Biochemical pharmacology.
[237] J. Cummings,et al. Re-evaluation of the molecular pharmacology of mitomycin C. , 1995, European journal of cancer.
[238] C. Monneret,et al. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation. , 1998, Anti-cancer drug design.
[239] S. Papot,et al. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs. , 1998, Bioorganic & medicinal chemistry letters.
[240] P. Su,et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. , 1991, Bioconjugate chemistry.
[241] L. H. Patterson. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent , 1993, Cancer and Metastasis Reviews.
[242] D. Waxman,et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[243] P. Workman,et al. DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.
[244] D. Ross,et al. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. , 1996, Biochemical pharmacology.
[245] M. Kelner,et al. Distribution of microsomal glutathione transferase 1 in mammalian tissues. A predominant alternate first exon in human tissues. , 1999, European journal of biochemistry.
[246] D. Kerr,et al. Virus-directed enzyme prodrug therapy using CB1954. , 1999, Anti-cancer drug design.
[247] R. Barker,et al. The genetic and biochemical properties of the D‐amino acid oxidases in human tissues , 1977, Annals of human genetics.
[248] K. Nakanishi,et al. Studies on Menadione Reductase of Bakers' Yeast:I. Purification, Crystallization and Some Properties , 1963 .
[249] P. Danenberg,et al. Thymidylate synthase inhibitors. , 1999, Seminars in oncology.
[250] J. Hartley,et al. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. , 2000, Frontiers in bioscience : a journal and virtual library.
[251] G. Koren,et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. , 2000, Life sciences.
[252] K. Kurtz. Studies on the mechanism of D-amino acid oxidase , 2000 .
[253] A. Harris,et al. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. , 1994, International journal of radiation oncology, biology, physics.
[254] W. Smythe. Prodrug/drug sensitivity gene therapy: Current status , 2000, Current oncology reports.
[255] D. Ross,et al. Enzymology of bioreductive drug activation. , 1996, The British journal of cancer. Supplement.
[256] T. Satoh,et al. Molecular aspects of carboxylesterase isoforms in comparison with other esterases. , 1995, Toxicology letters.
[257] H. Haisma,et al. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX‐GA3 in combination with a monoclonal antibody β‐glucuronidase conjugate , 2001, International journal of cancer.
[258] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[259] J. M. Noronha,et al. Studies on the enzymatic hydrolysis of polyglutamyl folates by chicken liver folyl poly-gamma-glutamyl carboxypeptidase. I. Intracellular localization, purification and partial characterization of the enzyme. , 1977, Biochimica et biophysica acta.
[260] P. Carter,et al. Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug , 1995 .
[261] Hiromasa Takahashi,et al. Intratumoral pyrimidine nucleoside phosphorylase (pynpase) activity predicts a selective effect of adjuvant 5’-deoxy-5-fluorouridine (5’ dfur) on breast cancer , 2000, Breast cancer.
[262] D. Moss. Perspectives in alkaline phosphatase research. , 1992, Clinical chemistry.
[263] S. Spencer,et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. , 1998, International journal of radiation oncology, biology, physics.
[264] I. Stratford,et al. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. , 1997, British Journal of Cancer.
[265] D. Meyer,et al. Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: substrates for an antibody targeted enzyme , 1992 .
[266] T. Satoh,et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.
[267] G. Murray,et al. Cytochrome P450 expression in tumours. , 1995, The Journal of pathology.
[268] J. Kadow,et al. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. , 1992, Bioconjugate chemistry.
[269] D. Ross,et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. , 2001, Biochemical pharmacology.
[270] J. Roberts,et al. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) , 1991, Biochemical pharmacology.
[271] J. Chern,et al. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. , 1991, Biochemical pharmacology.
[272] K. Tew,et al. Cellular response to a glutathione S-transferase P1-1 activated prodrug. , 2000, Molecular pharmacology.
[273] D. Johns. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. , 1967, The Journal of clinical investigation.
[274] M. Bibby,et al. A preclinical pharmacokinetic study of the bioreductive drug AQ4N. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[275] R. Moreira,et al. Cleavage of tertiary amidomethyl ester prodrugs of carboxylic acids by rat liver homogenates. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[276] V. Schaeffer,et al. Immunohistochemical localization of glutamine transaminase K, a rat kidney cysteine conjugate beta-lyase, and the relationship to the segment specificity of cysteine conjugate nephrotoxicity. , 1988, Molecular pharmacology.
[277] R. Crystal. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors , 1999, Cancer Chemotherapy and Pharmacology.
[278] J. Montgomery,et al. Analogs of 6-methyl-9-beta-D-ribofuranosylpurine. , 1968, Journal of medicinal chemistry.
[279] L. Kauvar,et al. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. , 1998, Cancer research.
[280] N. Vermeulen,et al. Evaluation of the kinetics of beta-elimination reactions of selenocysteine Se-conjugates in human renal cytosol: possible implications for the use as kidney selective prodrugs. , 2000, The Journal of pharmacology and experimental therapeutics.
[281] H. Sies,et al. Chemistry of biologically important synthetic organoselenium compounds. , 2001, Chemical reviews.
[282] J. A. Nelson,et al. Targeting 6-thioguanine to the kidney with S-(guanin-6-yl)-L-cysteine. , 1995, The Journal of pharmacology and experimental therapeutics.
[283] A. Stavrovskaya. Cellular mechanisms of multidrug resistance of tumor cells. , 2000, Biochemistry. Biokhimiia.
[284] H. W. Scheeren,et al. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. , 1997, Bioorganic & medicinal chemistry.
[285] M. Wierdl,et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. , 2001, Cancer research.
[286] C. Punt. New drugs in the treatment of colorectal carcinoma , 1998, Cancer.
[287] A. Photiou,et al. Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma. , 1999, Bioorganic & medicinal chemistry.
[288] J. J. Roberts,et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). , 1988, Biochemical pharmacology.
[289] J. Hayes,et al. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.
[290] K. Ziaja,et al. Neoplastic lesions of the human liver in relation to the activity of the cytochrome P-450 dependent monooxygenase system. , 2000, Medical science monitor : international medical journal of experimental and clinical research.
[291] W. Schlage,et al. Melanogenesis in genetically determined pigment cell tumors of platyfish and platyfish-swordtail hybrids: correlation between tyrosinase activity and degree of malignancy , 1977, Zeitschrift für Krebsforschung und Klinische Onkologie.
[292] A. Cheng,et al. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. , 1991, Biochemical pharmacology.
[293] A A Elfarra,et al. Cysteine conjugate beta-lyase activity in human renal carcinomas. , 1995, Cancer biochemistry biophysics.
[294] A. Elfarra,et al. Cysteine S-conjugates may act as kidney-selective prodrugs: formation of 6-mercaptopurine by the renal metabolism of S-(6-purinyl)-L-cysteine. , 1989, The Journal of pharmacology and experimental therapeutics.
[295] N. Di Lascio,et al. Tissue distribution of drug-metabolizing enzymes in humans. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.
[296] A. D. Rodrigues,et al. Enzyme kinetics of cytochrome P450-mediated reactions. , 2012, Current drug metabolism.
[297] D. L. Dewey,et al. Hydroxyanisole‐induced regression of the Harding‐Passey melanoma in mice , 1977, The Journal of pathology.
[298] K. Mimori,et al. Up-regulated pyrimidine nucleoside phosphorylase in breast carcinoma correlates with lymph node metastasis. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[299] G. Peters,et al. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. , 1989, British Journal of Cancer.
[300] L. Kèlland,et al. Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol. , 2000, Anti-cancer drug design.
[301] H. Ishitsuka,et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. , 1998, Cancer research.
[302] Dietmar Schomburg,et al. Enzyme Handbook 15 , 1998, Springer Berlin Heidelberg.
[303] H. Hwang,et al. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[304] M Nomura,et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.
[305] K Chiba,et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[306] W. Bloomer,et al. Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol andN-acetyl-4-S-cysteaminylphenol , 2004, Cancer Chemotherapy and Pharmacology.
[307] C. A. Ramsden,et al. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. , 1997, European journal of cancer.
[308] J. Grem,et al. Thymidylate synthase inhibitors. , 2001, Cancer chemotherapy and biological response modifiers.
[309] J. Nemunaitis,et al. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. , 2001, Human gene therapy.
[310] M. Jaffar,et al. The rôle of thymidine phosphorylase/PD-ECGF in cancer chemotherapy: a chemical perspective. , 1999, Anti-cancer drug design.
[311] R. Lowenthal,et al. Toxicity of chemotherapy. , 1996, Hematology/oncology clinics of North America.
[312] F. Moolten. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.
[313] K. Jimbow,et al. Comparison of in vitro cytotoxicity of N‐acetyl and N‐propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity , 2000, Melanoma research.
[314] H. Böhm,et al. Enzyme Handbook Vol. 1. Class 4: Lyases. Herausgegeben von D. Schomburg und M. Salzmann. Loseblattsammlung 1159 Seiten. Springer-Verlag, Berlin, Heidelberg, New York u. a. 1990. Preis: 248.– DM , 1992 .
[315] D. Scudiero,et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[316] G. Stamp,et al. Protein extraction and western blotting from methacarn‐fixed tissue , 1995, The Journal of pathology.
[317] Y. Moriwaki,et al. Immunohistochemical localization of aldehyde and xanthine oxidase in rat tissues using polyclonal antibodies , 2005, Histochemistry and Cell Biology.
[318] C. Monneret,et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. , 1998, Journal of medicinal chemistry.
[319] K. Korzekwa,et al. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. , 1991, Cancer research.
[320] O. Sansom,et al. In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine. , 2000, Carcinogenesis.
[321] A. Photiou,et al. Melanocyte-Directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma. , 2001, Bioorganic & medicinal chemistry.
[322] A. Elfarra,et al. Kidney-selective prodrugs of 6-mercaptopurine: biochemical basis of the kidney selectivity of S-(6-purinyl)-L-cysteine and metabolism of new analogs in rats. , 1991, The Journal of pharmacology and experimental therapeutics.
[323] J. Backman,et al. The role of beta-glucuronidase in drug disposition and drug targeting in humans. , 1997, Clinical pharmacokinetics.
[324] M. Okamoto,et al. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. , 1984, Japanese journal of pharmacology.
[325] D. Haller,et al. UFT in the treatment of colorectal and breast cancer. , 2001, Oncology.
[326] P. Senter,et al. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. , 1991, Bioconjugate chemistry.
[327] T. Spector,et al. 5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. , 1994, Biochemical pharmacology.
[328] L. H. Patterson,et al. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[329] A. Harris,et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. , 2000, Biochemical pharmacology.
[330] H. Yamazaki,et al. Rat Cytochrome P 450 1 A and 3 A Enzymes Involved in Bioactivation of Tegafur to 5-Fluorouracil and Autoinduced by Tegafur in Liver Microsomes , 2001 .
[331] J. E. Kudlow,et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells , 2000, Gene Therapy.
[332] S. Kaul,et al. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. , 1996, Seminars in oncology.
[333] N. Siemers,et al. Development and activities of a new melphalan prodrug designed for tumor-selective activation. , 1998, Bioconjugate chemistry.
[334] L. Presta,et al. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. , 1995, Cancer research.
[335] M. Walker,et al. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.
[336] J. J. Starling,et al. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. , 1995, Bioconjugate chemistry.
[337] M. Ratain,et al. Pharmacogenetics and cancer chemotherapy. , 1998, European journal of cancer.
[338] Arthur J. L. Cooper. Mechanisms of cysteine S-conjugate beta-lyases. , 2006, Advances in enzymology and related areas of molecular biology.
[339] G. H. Coombs,et al. Trifluoromethionine, a Prodrug Designed against Methionine γ-Lyase-Containing Pathogens, Has Efficacy In Vitro and In Vivo against Trichomonas vaginalis , 2001, Antimicrobial Agents and Chemotherapy.
[340] H. Tojo,et al. Immunochemical relationship of D-amino acid oxidases in various tissues and animals. , 1991, Comparative biochemistry and physiology. B, Comparative biochemistry.
[341] T. Chan,et al. Differences in deoxycytidine metabolism in mouse and rat. , 1983, The Biochemical journal.
[342] M. Mareel,et al. Antitumor Drug Radiation Interactions , 1990 .
[343] R. Varón,et al. Catalytic oxidation of 2,4,5-trihydroxyphenylalanine by tyrosinase: identification and evolution of intermediates. , 1992, Biochimica et biophysica acta.
[344] H. Ganther,et al. In vitro effects of Se-allylselenocysteine and Se-propylselenocysteine on cell growth, DNA integrity, and apoptosis. , 2000, Biochemical pharmacology.